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Abstract
Introduction: In this study, we sought to examine whether pharmacological postconditioning with sevoflurane
(SEVO) is neuro- and cardioprotective in a pig model of cardiopulmonary resuscitation.
Methods: Twenty-two pigs were subjected to cardiac arrest. After 8 minutes of ventricular fibrillation and 2
minutes of basic life support, advanced cardiac life support was started. After successful return of spontaneous
circulation (N = 16), animals were randomized to either (1) propofol (CONTROL) anesthesia or (2) SEVO anesthesia
for 4 hours. Neurological function was assessed 24 hours after return of spontaneous circulation. The effects on
myocardial and cerebral damage, especially on inflammation, apoptosis and tissue remodeling, were studied using
cellular and molecular approaches.
Results: Animals treated with SEVO had lower peak troponin T levels (median [IQR]) (CONTROL vs SEVO = 0.31 pg/
mL [0.2 to 0.65] vs 0.14 pg/mL [0.09 to 0.25]; P < 0.05) and improved left ventricular systolic and diastolic function
compared to the CONTROL group (P < 0.05). SEVO was associated with a reduction in myocardial IL-1b protein
concentrations (0.16 pg/μg total protein [0.14 to 0.17] vs 0.12 pg/μg total protein [0.11 to 0.14]; P < 0.01), a
reduction in apoptosis (increased procaspase-3 protein levels (0.94 arbitrary units [0.86 to 1.04] vs 1.18 arbitrary
units [1.03 to 1.28]; P < 0.05), increased hypoxia-inducible factor (HIF)-1a protein expression (P < 0.05) and
increased activity of matrix metalloproteinase 9 (P < 0.05). SEVO did not, however, affect neurological deficit score
or cerebral cellular and molecular pathways.
Conclusions: SEVO reduced myocardial damage and dysfunction after cardiopulmonary resuscitation in the early
postresuscitation period. The reduction was associated with a reduced rate of myocardial proinflammatory cytokine
expression, apoptosis, increased HIF-1a expression and increased activity of matrix metalloproteinase 9. Early
administration of SEVO may not, however, improve neurological recovery.
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Introduction
Approximately 1 million sudden cardiac arrests occur
each year in the United States and Europe [1]. Although
the initial return of spontaneous circulation (ROSC)
after cardiac arrest (CA) is achieved in about 30% to
40% of cases, only 10% to 30% of these patients
admitted to the hospital are discharged with good neu-
rological outcomes. The rest of these patients die during
their hospital stay or survive but with neurological
sequelae [2].
Organ dysfunction following successful cardiopulmon-
ary resuscitation (CPR) has been attributed mainly to
the so-called postresuscitation disease, which is typically
characterized by circulatory failure, brain damage, sys-
temic inflammatory response syndrome and alterations
in coagulopathy [3]. Postresuscitation myocardial dys-
function is a critical issue and has been reported in 45%
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logical impairment after successful CPR is due mostly to
ischemic and/or hypoxic lesions and secondary reperfu-
sion injury to the brain [6].
Pharmacological postconditioning may offer an attrac-
tive opportunity to reduce damage to the myocardium
and brain within the postresuscitation period. Although
pharmacological postconditioning with the volatile anes-
thetic isoflurane has been shown to attenuate myocar-
dial injury after acute myocardial infarction [7] and to
reduce neurohistopathological injury after focal cerebral
ischemia [8], its potential protective properties have not
yet been investigated in the setting of global ischemia
and reperfusion. We hypothesized that the volatile anes-
thetic sevoflurane (SEVO), when administered during
reperfusion after successful CPR, reduces myocardial
dysfunction and neurological deficits.
Materials and methods
This project was approved by the Animal Investigation
Committee of the University Schleswig-Holstein, Cam-
pus Kiel, Kiel, Germany, and animals were managed in
accordance with the guidelines of the University Schles-
wig-Holstein, Campus Kiel, Kiel, Germany and the
Utstein-style guidelines [9]. All animals received human
care in compliance with the Guide for the Care and Use
of Laboratory Animals published by the National Insti-
tute of Health (NIH Publication 88.23, revised 1996).
Fully detailed methods and protocols are available in
Additional files 1 and 2.
Animal preparation
In this experimental study, we used 22 healthy Goettin-
ger miniature pigs, ages 2 to 4 years, of both genders
and weighing 40 to 50 kg. The animals were fasted over-
night but had free access to water. Anesthesia was
initiated by intramuscular injection of azaperone (4 mg/
kg) and atropine (0.01 mg/kg), completed by ear vein
injection of propofol (CONTROL) (1 to 2 mg/kg) and
sufentanil (0.2 μg/kg). After endotracheal intubation,
pigs were ventilated with a volume-controlled ventilator
(Sulla 808-V; Dräger AG, Lübeck, Germany) under the
following conditions: fraction of inspired oxygen (FiO2)
of 0.4 at 20 breaths/minute, tidal volume of 8 ml/kg to
maintain normocapnia and positive end-expiratory pres-
sure of 5 cm H2O. Ventilation was monitored using an
inspired/expired gas analyzer that measures oxygen and
end-tidal carbon dioxide volume (suction rate, 200 ml/
minute) (M-PRESTN monitor; Datex-Ohmeda Inc, Hel-
sinki, Finland). Total intravenous anesthesia was main-
tained by continuous infusion of propofol (4 mg/kg/
hour) and sufentanil (0.2 μg/kg/hour). No neuromuscu-
lar blocking agent was administered in this study. Ring-
er’s solution (10 ml/kg/hour) was administered
continuously. A standard lead II electrocardiogram
(ECG) was used to monitor cardiac rhythm. To ensure
an appropriate depth of anesthesia, we took indirect
measurements such as tail-clamping, monitoring of the
corneal reflex, and lacrimation, as well as changes in
hemodynamics and heart rate. If our assessment sug-
gested inadequate level of anesthesia, additional sufenta-
nil or propofol was injected.
A saline-filled central venous catheter (7-French) was
inserted in the right internal jugular vein for drug
administration. A thermistor-tipped catheter (4-French)
for arterial thermodilution (PULSION Medical Systems
SE, Munich, Germany) was inserted percutaneously into
the right femoral artery. The arterial catheter was con-
nected to the PiCCO system (PiCCO plus version 6.0
software; PULSION Medical Systems SE), and the
resulting signal was processed to determine mean arter-
ial blood pressure, heart rate and blood temperature. In
addition, the arterial catheter allowed discontinuous
measurement of transpulmonary cardiac output by
injecting 10 ml of ice-cold saline into the proximal port
of the central venous catheter. The mean of three con-
secutive measurements randomly assigned to the
respiratory cycle was used for determination of cardiac
output. Correction for cardiac index was made by calcu-
lating body surface using the formula described pre-
viously for pigs [10]. Intravascular catheters were
attached to pressure transducers (Smiths Medical,
Kirchseeon, Germany) that were aligned at the level of
the right atrium. All catheters were flushed with isotonic
saline containing 5 IU/ml heparin at a rate of 3 ml/hour
to prevent obstruction. Core body temperature was
monitored continuously via the arterial catheter. Nor-
mothermic body temperature was maintained at 37.0°C
to 38.0°C in all animals with a heating blanket through-
out the study period.
Experimental setting
The experimental time line is presented in Figure 1. Fol-
lowing hemodynamic measurements at baseline, ventri-
cular fibrillation (VF) was electrically induced by an
alternating current of 5 to 10 V and 1 to 2 mA by a 5-
French pacing catheter that was advanced into the right
ventricle via the left internal jugular vein, while mechan-
ical ventilation was discontinued. To prevent clot forma-
tion, the animals received heparin (100 IU/kg) prior to
induction of CA. After an 8-minute nonintervention
interval of untreated VF, basic life support CPR was
simulated for 2 minutes applying external manual chest
compressions at a rate of 100 per minute with a 50%
duty cycle, a compression depth of 25% of the anterior-
posterior diameter of the chest wall, and a compression-
to-ventilation ratio of 30:2. Subsequently, advanced car-
diac life support was started with one 100 J biphasic
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ical Corp, Chelmsford, USA) according to one-shock
protocol. Further, ventilations were performed with
100% oxygen at 20 breaths/minute during CPR. All pigs
received 45 μg/kg epinephrine and 0.4 U/kg vasopressin
alternating. ROSC was defined as maintenance of an
u n a s s i s t e dp u l s ea n das y s t o l i ca o r t i cb l o o dp r e s s u r eo f
≥ 60 mm Hg lasting for 10 consecutive minutes accord-
ing to the Utstein-style guidelines [9]. Since neurological
recovery is very unlikely after 30 minutes of normother-
mic CA, CPR was terminated, when resuscitation
remained unsuccessful.
Immediately after ROSC, animals were randomized
either to (1) total intravenous anesthesia that was main-
tained by continuous infusion of propofol (4 mg/kg/h)
or (2) the volatile anesthetic SEVO. As we recently
found beneficial cardioprotective effects by interrupted
SEVO compared with continuous SEVO administration
in coronary artery surgery [11], postconditioning was
initiated with 3 interrupted cycles of wash-in (6% end-
tidal volume for 5 minutes) and wash-out (0.5% end-
tidal volume for 5 minutes) followed by a continuous
administration of 1.5 minimum alveolar concentration
SEVO (3% end-tidal volume) for 4 hours. In both
groups sufentanil was administered at a rate of 0.2 μg/
kg/h. FiO2 was reduced to 0.4 fifteen minutes after
ROSC to avoid hyperoxia [12]. Since animals were ran-
domized either to propofol or SEVO not until after
ROSC, we used propofol before VF in all animals.
During the initial postresuscitation period, animals
received crystalloid infusions to keep mean arterial
blood pressure above 50 mm Hg, central venous pres-
sure above 5 mm Hg, and cardiac index at baseline
values ± 10%. If this first step failed, additional epi-
nephrine was administered to keep mean arterial blood
pressure above 50 mm Hg. We further aimed at serum
glucose levels less than 150 mg/dL by intermittent insu-
lin bolus administration. F o u rh o u r sa f t e rR O S C ,a n i -
mals received intramuscular injection of 2 to 3 mg/kg
tramadol for pain relief and were weaned from the ven-
tilator. Following extubation, each animal was observed
for two hours to ensure adequate spontaneous breathing
before being returned to their cages. Twenty-four hours
after ROSC, animals were again anesthetized as
described above using propofol. After hemodynamic and
echocardiographic data were obtained animals were
killed by an overdose of sufentanil, propofol and potas-
sium chloride, and tissue samples of the myocardium
and cerebral cortex were collected and immediately
snap-frozen in liquid nitrogen (stored at -80°C). Autopsy
was routinely performed for documentation of potential
injuries to the thoracic and abdominal cavity during
CPR.
Measurements
The cumulative defibrillation energy, vasopressor dose,
time to ROSC and coronary perfusion pressure were
recorded during CPR to ensure comparable ischemia
time intervals between groups. Hemodynamic variables,
echocardiographic data, cumulative fluid load and
cumulative epinephrine dose were recorded at baseline
and repetitively up to 24 hours after successful ROSC.
Echocardiography
Two-dimensional and pulsed wave Doppler transesopha-
geal echocardiography was performed by a single
Figure 1 Experimental time line. Twenty-two pigs were subjected to cardiac arrest. After 8 minutes of ventricular fibrillation (VF), pigs were
resuscitated (cardiopulmonary resuscitation, CPR). Immediately after successful return of spontaneous circulation (ROSC; N = 16), the animals
were randomized to either (1) total intravenous anesthesia maintained by continuous infusion of propofol (4 mg/kg/hour; CONTROL) or (2) the
volatile anesthetic sevoflurane (SEVO) at 1.5 minimum alveolar concentration (3% end-tidal volume) with an initial three interrupted cycles of
wash-in (6% end-tidal volume for 5 minutes) and wash-out (0.5% end-tidal volume for 5 minutes) for 4 hours. Neurological function was
assessed 24 hours after ROSC by neurological deficit score (NDS) of 1 or 2. Subsequently, animals were again anesthetized using propofol to
determine myocardial function by echocardiography, then the animals were killed by an overdose of anesthetic to collect myocardial and
cerebral tissue samples. cTnT = cardiac troponin T; TEE = transesophageal echocardiography.
Meybohm et al. Critical Care 2011, 15:R241
http://ccforum.com/content/15/5/R241
Page 3 of 12experienced examiner using a Vivid I Cardiovascular
Ultrasound System (GE Healtcare, Munich, Germany)
with an omniplane probe as described before [13]. The
left ventricle end-systolic and end-diastolic volumes
were estimated using a four-chamber view by tracing
the endocardial border, including the papillary muscles
and the method of disks according to the modified
Simpson’s rule algorithm, then the left ventricular ejec-
tion fraction was obtained. For further details, please
refer to Additional file 1, Supplemental digital content:
methods S1.
Determination of serum markers and blood gases
Arterial oxygen and carbon dioxide partial pressures and
blood glucose levels were measured by using an auto-
matic blood gas analyzer (GEM 4000; Instrumentation
Laboratory GmbH, Munich, Germany). For determina-
tion of serum markers, arterial blood samples were col-
lected at baseline and 1, 2, 4 and 24 hours after ROSC.
Serum was obtained (centrifugation at 3,000 × g for 5
minutes) and stored at -20°C until determination of car-
diac troponin T by an independent laboratory (Institute
of Clinical Chemistry, University Hospital Schleswig-
Holstein, Campus Kiel, Kiel, Germany).
Ventricular arrhythmia
All animals underwent 24-hour ECG recording. Com-
mercially available software was used to detect ventricu-
lar arrhythmias (CardioDay Holter ECG; Getemed,
Teltow, Germany). All recordings were reviewed and
edited by a well-trained technician blinded to the treat-
ment group. The total number of ventricular premature
beats, bigeminy, ventricular tachycardia (defined as at
least four consecutive complexes lasting at least 120
milliseconds) and VF were counted over an interval of
30 minutes immediately after ROSC and 24 hours later
in accordance with the Lambeth Convention [14].
Neurological evaluation
Overall neurological performance was evaluated at 24
hours after ROSC using two different neurological def-
icit scores (NDSs 1 and 2) that have been reported
previously. The tests consist of different items repre-
senting the level of consciousness, respiration, motor
and sensory function, posture and feeding behavior.
The scores assign different values, depending on the
severity of deficits in neurological function, so that a
score of 0 is normal and scores of 100 (NDS 1) [15]
and 400 (NDS 2) [16] indicate brain death, respec-
tively. Please refer to Additional file 2 which contain
two tables showing calculations of NDS 1 (Additional
file 2: Table S1) and NDS 2 (Additional file 2: Table
S2), respectively.
Western blot analysis
Caspases are proteases involved in the apoptotic and
inflammatory cascade, and caspase-3 in particular is a
central mediator of the apoptotic cascade [17]. To quan-
tify apoptosis, we determined uncleaved procaspase-3 by
Western blot analysis. In addition, protein expression of
hypoxia- and/or ischemia-associated hypoxia-inducible
factor (HIF)-1a was evaluated by Western blot analysis.
For further details, please refer to Supplemental digital
content: methods S1.
Semiquantitative RT-PCR
Transcript levels of IL-1b, caspase-3, Fas ligand, HIF-1a,
matrix metalloproteinase (MMP)-9 and MMP-2 were
investigated in myocardial and cerebral cortical tissue
and compared between the CONTROL and SEVO
groups. For further details, please refer to Supplemental
digital content: methods S1.
ELISA
Protein concentrations of IL-1b were determined by
using a swine-specific ELISA system (BioSource Interna-
t i o n a l ,I n c ,C a m a r i l l o ,C A ,U S A )i nh o m o g e n a t e so f
myocardial and cerebral tissues according to the manu-
facturer’s protocol and relativized to the amount of total
protein in the respective sample.
Gelatin zymography activity of MMP-9 and MMP-2
Zymography was performed as described previously [13]
to detect MMP-9 and MMP-2 activity in myocardial
and cerebral tissues. For further details, please refer to
Supplemental digital content: methods S1.
Statistics
Sample size was calculated based on methods described
i nap r e v i o u ss t u d y[ 1 8 ]t od e t e c tad i f f e r e n c ew i t h
respect to left ventricular ejection fraction of 25% as the
primary end point. We calculated a sample size of seven
animals in each group to reach an a of 0.05 and power
of 80%. To account for animals that did not achieve
ROSC or died during the postresuscitation period, we
used 11 animals per group. Statistics were performed
using commercially available statistical software (Graph-
Pad Prism version 5.02 for Windows; GraphPad Soft-
ware, San Diego, CA, USA). Data were analyzed by
Mann-Whitney U test and two-way repeated-measures
analysis of variance. In cases where significant differ-
ences were observed, the data were adjusted for multiple
comparisons (Bonferroni correction). Variables are
expressed as means × SD or box-and-whisker plots
unless otherwise specified. The figures shows box whis-
kers with medians [25th to 75th percentile] and the
minimum and maximum values (ends of the whiskers).
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value ≤ 0.05.
Results
Survival of animals
Sixteen of twenty-two animals were successfully resusci-
tated. Detailed resuscitation data are presented in Table
1. Among the animals successfully resuscitated, seven of
eight survived for 24 hours in the CONTROL group
compared to all eight animals in the SEVO group. One
animal in the CONTROL group died as a result of hemo-
dynamic instability during the postresuscitation period.
Myocardial dysfunction and damage
At baseline, there were no differences with respect to
hemodynamic and echocardiographic data, glucose levels
and variables of gas exchange. Analysis of echocardio-
graphic data revealed significant (P < 0.05) improved left
ventricular ejection fraction as the primary end point,
myocardial performance index and E/A ratio (the ratio
between early (diastolic, E) and late (atrial, A) ventricu-
lar filling velocity) in the SEVO group compared with
the CONTROL group in the initial period after ROSC,
whereas groups did not differ significantly 24 hours
after ROSC (Figures 2A through 2C). Animals treated
with SEVO had lower peak serum levels of cardiac tro-
ponin T 4 hours after ROSC compared with the CON-
TROL group (P < 0.05) (Figure 2D). Further systemic
hemodynamic variables are presented in Table 2. Cumu-
lative fluid load and cumulative epinephrine dose within
4 hours following ROSC did not significantly differ
between the CONTROL group (fluid = 1,301 ± 412 mL
and epinephrine = 30 ± 9 μg/kg) and the SEVO group
( f l u i d=1 , 2 7 9±3 7 4m La n de p i n e p h r i n e=2 4±1 1μg/
kg) (data not shown). The incidence of ventricular pre-
mature beats tended to be decreased in the SEVO group
compared to the CONTROL group (Table 3).
Cellular mechanisms associated with myocardial
dysfunction and damage
Compared to the CONTROL group, SEVO reduced
both expression of IL-1b mRNA levels (CONTROL vs
SEVO: 0.58 arbitrary units (a.u.) [0.4 to 0.76] vs 0.53 a.
u. [0.26 to 0.65]; not significant) (Figure 3A) and IL-1b
protein concentrations (CONTROL vs SEVO; 0.16 pg/
μg total protein [0.14 to 0.17] vs 0.12 pg/μg total pro-
tein [0.11 to 0.14]; P < 0.01) (Figure 3B). Although
mRNA expression of caspase-3 did not differ signifi-
cantly between the groups (CONTROL 0.87 a.u. [0.82
to 1.11] vs SEVO 1.0 a.u. [0.90 to 1.11]; data not
shown), mRNA expression of Fas ligand was signifi-
cantly decreased in the SEVO group (CONTROL vs
SEVO: 0.68 a.u. [0.62 to 0.76] vs 0.61 a.u. [0.56 to
0.67]; P < 0.05) (Figure 3C) and uncleaved inactive
procaspase-3 was significantly increased in the SEVO
group (CONTROL vs SEVO: 0.94 a.u. [0.86 to 1.04] vs
1.18 a.u. [1.03 to 1.28]; P < 0.05) (Figure 3D). In addi-
tion, both mRNA and protein expression of HIF-1a
was increased in the SEVO group (CONTROL vs
SEVO mRNA: 0.73 a.u. [0.71 to 0.89] vs 0.96 a.u. [0.85
to 1.07]; not significant; CONTROL vs SEVO protein:
0.60 a.u. [0.48 to 0.75] vs 0.78 a.u. [0.69 to 0.89]; P <
0.05) (Figures 3E and 3F). Although mRNA expression
of MMP-9 and MMP-2 did not differ between groups
(CONTROL vs SEVO MMP-9: 0.07 a.u. [0.04 to 0.29]
vs 0.05 a.u. [0.05 to 0.21]; CONTROL vs SEVO MMP-
2: 1.31 a.u. [1.25 to 1.67] vs 1.56 a.u. [1.45 to 1.62];
data not shown), SEVO significantly increased MMP-9
activity (CONTROL vs SEVO; 18.5 a.u. [15.9 to 19.7]
vs 23.5 a.u. [18.7 to 28.3]; P < 0.05) (Figure 3G) and
did not affect MMP-2 activity (CONTROL vs SEVO:
37.5 a.u. [27.7 to 51.4] vs 33.6 a.u. [29.7 to 37.3]; not
significant) (Figure 3H).
Neurological dysfunction
Twenty-four hours after ROSC, most of the animals
(NDS 1: seven of eight in the CONTROL group vs
five of eight in the SEVO group; NDS 2: seven of
eight in the CONTROL group vs six of eight in the
SEVO group) showed neurological deficits, including
unsteady gait, irritable consciousness and abnormal
respiration. Nevertheless, we did not find any differ-
ences between the CONTROL and SEVO groups (Fig-
ures 4A and 4B).
Table 1 Cardiopulmonary resuscitation data
Measurement parameters CONTROL (N = 8) SEVO (N =8 ) P-values
24-hour survival rate (n) 7 8 1.0
a
Time to ROSC (minutes) 6.8 ± 1.7 6.6 ± 3.2 0.596
Cumulative epinephrine dose (μg/kg) 30 ± 9 24 ± 11 0.309
Cumulative vasopressin dose (IU/kg) 0.6 ± 0.2 0.5 ± 0.2 0.225
Cumulative defibrillation energy (J) 527 ± 230 528 ± 457 0.595
CorPP (mmHg) 38 ± 9 36 ± 6 0.916
CONTROL = propofol; CorPP = coronary perfusion pressure 10 minutes after induction of ventricular fibrillation; ROSC = return of spontaneous circulation; SEVO =
sevoflurane. Data are means ± SD.
aFisher’s exact test.
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dysfunction
In cerebral cortical tissue, we did not find any difference
between the CONTROL and SEVO groups with regard
to (1) expression of IL-1b mRNA levels (CONTROL vs
SEVO: 0.73 a.u. [0.7 to 0.87] vs 0.79 a.u. [0.73 to 0.84]),
(2) IL-1b protein concentrations (0.08 pg/μgt o t a l
protein [0.08 to 0.1] vs 0.1 pg/μg total protein [0.09 to
0.1]), (3) expression of caspase-3 mRNA (0.94 a.u. [0.82
to 1.04] vs 0.89 a.u. [0.86 to 1.0]), (4) Fas ligand mRNA
(0.47 a.u. [0.36 to 0.6] vs 0.41 a.u. [0.34 to 0.51]), (5)
uncleaved inactive procaspase-3 (1.27 a.u. [0.29 to 2.56]
vs 0.68 a.u. [0.38 to 2.41]) and (6) expression of HIF-1a
(mRNA: 1.11 a.u. [1.07 to 1.16] vs 1.19 a.u. [1.11 to
Figure 2 Myocardial dysfunction and damage. At baseline (BL) and 1, 2, 4 and 24 hours after return of spontaneous circulation (ROSC), left
ventricular ejection fraction (A), myocardial performance index (B) and E/A ratio (the ratio between early (diastolic, E) and late (atrial, A)
ventricular filling velocity) (C) were evaluated by transesophageal echocardiography, and cardiac troponin T serum values (D) were quantified in
the propofol (CONTROL) and sevoflurane (SEVO) groups.
#P < 0.05 vs CONTROL.
Table 2 Hemodynamic data
Clinical parameters HR (beats/minute) MAP (mmHg) CVP (mmHg) CI (L/minute/m
2)
Baseline
CONTROL 57 ± 21 88 ± 33 5 ± 2 3.8 ± 0.5
SEVO 65 ± 11 71 ± 14 4 ± 2 3.8 ± 0.7
1-hour ROSC
CONTROL 116 ± 26 82 ± 8 8 ± 3 4.4 ± 1.3
SEVO 108 ± 11 74 ± 19 7 ± 2 5.1 ± 0.9
2-hour ROSC
CONTROL 95 ± 19 76 ± 17 6 ± 1 4.4 ± 1.0
SEVO 109 ± 12 81 ± 13 6 ± 1 5.7 ± 1.7
4-hour ROSC
CONTROL 97 ± 21 76 ± 16 8 ± 2 5.0 ± 1.7
SEVO 101 ± 19 74 ± 13 7 ± 2 5.5 ± 1.6
24-hour ROSC
CONTROL 75 ± 15 65 ± 9 8 ± 3 4.0 ± 0.8
SEVO 69 ± 15 69 ± 15 7 ± 2 3.4 ± 0.6
Hemodynamic data were determined at baseline and 1, 2, 4 and 24 hours after return of spontaneous circulation (ROSC) in the propofol (CONTROL) and
sevoflurane (SEVO) groups. Data are means ± SD. Heart rate (HR), mean arterial pressure (MAP), central venous pressure (CVP) and cardiac index (CI) did not
differ significantly between groups after we applied the Bonferroni correction for repeated time measurements using two-way analysis of variance. Cardiac index
was calculated as the ratio of cardiac output to body surface area (body surface area = 0.0734 × (body weight in kilograms)
0.656) [10].
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to 0.47]; data not shown). In addition, expression of
MMP-9 mRNA (CONTROL vs SEVO: 0.72 a.u. [0.68 to
0.82] vs 0.70 a.u. [0.62 to 0.71]), MMP-2 mRNA (0.91 a.
u. [0.91 to 0.99] vs 0.93 a.u. [0.89 to 0.97]; data not
shown) and activity of MMP-9 (44.3 a.u. [33.3 to 45.7]
vs 34.6 a.u. [23.6 to 62.4]) did not differ significantly,
whereas MMP-2 activity was significantly decreased in
the SEVO group (CONTROL vs SEVO: 34.8 a.u. [28.1
to 37.8] vs 22.0 a.u. [14.4 to 23.9]; P < 0.05).
Table 3 Ventricular arrhythmias
Clinical parameters CONTROL SEVO P-values
ROSC 30 minutes (n)
Ventricular premature beats 25 [19 to 41] 20 [13 to 42] 0.601
Bigeminy 1 [1 to 3] 2 [1 to 4] 0.651
VT/VF - - -
ROSC 24 hours (n)
Ventricular premature beats 8 [6 to 11] 5 [3 to 10] 0.346
Bigeminy 2 [2 to 5] 2 [1 to 4] 0.584
VT/VF - - -
The total number of ventricular premature beats, bigeminy, ventricular tachycardia (VT)/ventricular fibrillation (VF) ratio was counted over an interval of 30
minutes immediately after return of spontaneous circulation (ROSC) and over a 30-minute interval 24 hours later in the propofol (CONTROL) and sevoflurane
(SEVO) groups. Data are medians [25th to 75th percentiles]. Neither ventricular tachycardia nor ventricular fibrillation was observed in any group.
Figure 3 Cellular mechanisms associated with myocardial dysfunction and damage. Semiquantitative RT-PCR was used to analyze mRNA
expression of IL-1b (A), Fas ligand (C) and hypoxia-inducible factor (HIF)-1a (E) in myocardial tissue of the propofol (CONTROL) and sevoflurane
(SEVO) groups. GAPDH = glyceraldehyde 3-phosphate dehydrogenase. IL-1b protein concentrations were also determined by ELISA (B), and
Western blot analysis was used to evaluate protein expression of procaspase 3 (D) and HIF-1a (F). Detection of matrix metalloproteinase (MMP)-
9 (G) and MMP-2 activity (H) was performed by gelatin zymography. For further details, please refer to Additional file 1 Supplemental digital
content: methods S1.
#P < 0.05 vs CONTROL.
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Circulatory failure and myocardial dysfunction resulting
from CA largely contribute to morbidity and mortality
after initially successful CPR [19]. We have shown that
pharmacological postconditioning with SEVO, when
administered during reperfusion after successful CPR,
improved myocardial dysfunction and reduced myocar-
dial damage that was associated with attenuation of
myocardial inflammation, apoptosis, increased HIF-1a
expression and modulation of matrix remodeling. Based
on the present protocol, early administration of SEVO
did not, however, affect neurological recovery compared
to propofol.
Effects of sevoflurane on myocardial dysfunction and
damage
Most experimental studies have documented improved
cardiac performance when protective agents were given
before the insult [20]. In patients with CA, however,
pretreatment is virtually impossible because of the
unpredictable onset. Therefore, as in our study, protec-
tive interventions should be started at the earliest time
after the initiation of global reperfusion, when signifi-
cant damage has already occurred. Zhao and coworkers
[21], in an animal model of myocardial ischemia,
demonstrated that ischemic postconditioning during
reperfusion resulted in massive salvage of the myocar-
dium and reduction of myocardial infarct size by 45%.
In this context, pharmacological postconditioning with
volatile anesthetics may offer an attractive opportunity
to reduce organ damage in the postresuscitation period.
In our study, SEVO administered instead of propofol
during reperfusion after successful CPR attenuated
serum troponin T release. Thus SEVO administered
after ROSC reduced myocardial damage compared to
propofol in the early postresuscitation period.
Moreover, postresuscitation myocardial dysfunction is
one of the leading causes of early death after successful
CPR [22]. Echocardiography-derived variables such as
left ventricular ejection fraction and E/A ratio are used
routinely for assessment of myocardial function. In addi-
tion, the echocardiographic myocardial performance
index allows more sensitive and quantitative assessment
of postresuscitation myocardial dysfunction [23]. In the
present study, we found a deterioration of left ventricu-
lar performance in the initial postresuscitation period,
but not 24 hours after ROSC. More interestingly, both
left ventricular systolic and diastolic function were sig-
nificantly impaired after successful CPR, which remained
impaired in the CONTROL group but improved in the
SEVO group during the initial postresuscitation period.
After 24 hours of ROSC, however, no differences in sys-
tolic or diastolic function were detected. Upcoming stu-
dies must prove whether initial cardioprotective effects
afforded by volatile anesthetics result in long-term bene-
ficial effects. Russ et al.[ 2 4 ]a l s op r e v i o u s l yd e m o n -
strated, in a rat model of CA, that SEVO administered
at the beginning of CPR was able to improve left ventri-
cular ejection fraction, maximum cardiac power and
end-diastolic volume within the first 3 hours after CPR.
Since myocardial stunning has also previously been
summarized as one potential underlying mechanism of
postresuscitation myocardial dysfunction [22], attenua-
tion of myocardial stunning may further be considered
in terms of cardioprotective properties of SEVO post-
conditioning. In contrast, propofol is a widely used
intravenous anesthetic agent with antioxidant properties
secondary to its phenol-based chemical structure. From
a clinical point of view, potential hemodynamic side
effects (for example, hypotension) are reasonably com-
parable between propofol and SEVO. Mean arterial
pressure did not differ between both groups in our
study. It has been suggested that propofol itself may
even provide dose-dependent cardiac protection, primar-
ily by enhancing tissue antioxidant capacity and redu-
cing lipid peroxidation [25,26]. Therefore, it is unlikely
Figure 4 Neurological deficit scores. Twenty-four hours after ROSC most of the animals (NDS 1 (A): seven of eight CONTROL animals vs five of
eight SEVO animals; NDS 2 (B): seven of eight CONTROL animals vs six of eight SEVO animals) showed neurological deficits, including unsteady
gait, irritable consciousness and abnormal respiration. Nevertheless, we did not find any differences between the propofol anesthesia (CONTROL)
and sevoflurane anesthesia (SEVO) groups. For further details, please refer to Additional file 2: Supplemental digital content: methods S2.
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might potentially be attributed to increased myocardial
damage after propofol anesthesia.
Electrical instability with reperfusion ventricular
arrhythmia commonly occurs after CPR and may further
compromise postresuscitation survival. In the SEVO
group in our study, the incidence of postresuscitation
ventricular ectopic beats during the initial 30 minutes
following successful CPR tended to be decreased com-
pared to the CONTROL group, although statistical sig-
nificance was not reached. The mechanism by which
postconditioning with SEVO may reduce reperfusion-
induced ventricular arrhythmias may be independent of
known pathways that have been implicated in the
infarct-sparing effects of pre- and postconditioning,
including activation of adenosine, mitochondrial KATP
channel and mitochondrial permeability transition pore
pathways, respectively.
Effects of sevoflurane on myocardial apoptosis,
inflammation and remodeling
Adrie et al. [3] hypothesized that postresuscitation dis-
ease may be related to an early systemic inflammatory
response, leading to an exacerbation of the inflammatory
balance. Stress-induced proinflammatory cytokines, par-
ticularly TNF-a and IL-1b synthesized and released in
response to the stress of global ischemia accompanying
CA, play a pivotal role in development of postresuscita-
tion ventricular dysfunction [27]. In this respect, we
found that expression of IL-1b tended to be reduced on
the mRNA level and was statistically significantly
reduced on the protein level in the SEVO group com-
pared to the CONTROL group. In terms of inflamma-
tion, volatile anesthetics have been shown to reduce
neutrophil adhesion in the reperfused coronary system
and thereby preserve cardiac function [28]. Very
recently, Mu et al. [29] reported that isoflurane protects
against zymosan-induced generalized inflammation and
associated lung injury in mice by enhancing the activ-
ities of antioxidant enzymes. Therefore, volatile anes-
thetics may provide a new adjuvant strategy for the
treatment of critically ill patients. In parallel, pharmaco-
logical postconditioning might therefore also offer an
attractive opportunity to ameliorate damage to vital
organs in the postresuscitation period. Our data indicate
that SEVO resulted in less Fas ligand expression that
plays an important role in the regulation of apoptosis.
In this respect, we found an increase in procaspase-3 in
the SEVO group that could indicate less cleavage of this
protein, suggesting less apoptosis in the SEVO group
compared to CONTROL group. This is emphasized by
several studies demonstrating that SEVO pre- and post-
conditioning decrease ischemia-induced apoptosis [30]
by reduced activation of caspase-3 and caspase-9
mediated by phosphorylation of Akt and extracellular
signal-related kinases [31], as well as less release of cyto-
chrome c and caspase-3 activation mediated by
increased Bcl-2 expression and activation of NF-B [32].
Eckle et al. [33] provided evidence for a critical role of
HIF-1a in cardioprotection by ischemic preconditioning.
In addition, Zhao and colleagues [34] suggested recently
that HIF-1a is also involved in ischemic postcondition-
ing, and pharmacological augmentation of HIF-1a
expression may even enhance the myocardial infarct-
sparing effect. In the present study, expression of HIF-
1a was increased on mRNA and protein levels in the
SEVO group compared to the CONTROL group. Thus
our data confirm the results of several studies that
found upregulation of HIF-1a after preconditioning
with volatile anesthetics in both in vitro [35,36] and in
vivo [37] models of ischemia-reperfusion injury.
After substantial myocardial ischemia, major tissue
remodeling occurs to restore the structural architecture
and cardiac function. These remodeling events are par-
allel to increased expression and activity of MMPs in
the postinfarct myocardium [38]. The interaction
between global ischemia following CA, matrix remodel-
ing and volatile anesthetics has been poorly studied to
date.
Regarding the effect of SEVO on myocardial tissue
remodeling, we found that SEVO increased MMP-9
activity in myocardial tissue, whereas the effects on
MMP-2 activity were indistinguishable. Since IL-1b and
other proinflammatory cytokines may also be actively
involved in the regulation of matrix remodeling pro-
cesses after myocardial ischemia [39], the issue of tissue
remodeling and the regulatory effect of IL-1b on MMP
activity could be very important. Interestingly, in vitro
data from our group points toward positive regulatory
effects of IL-1b on MMP-2 and MMP-9 expression and
activity [40]. These data suggest that the SEVO-induced
attenuation of IL-1b expression in the present study
might affect myocardial MMP-2 and MMP-9 activity in
such a way as to facilitate tissue remodeling following
global ischemia and CPR.
Effects of sevoflurane on neurological function, cerebral
apoptosis and inflammation
Volatile anesthetics also possess a variety of neuropro-
tective mechanisms of action that include inhibition of
spontaneous depolarization in the ischemic penumbra,
antioxidant potential and N-methyl-D-aspartate receptor
antagonism after cerebral ischemia [41,42]. For example,
Blanck et al. [43] demonstrated functional reduction in
neurological injury following 8 minutes of CA after
SEVO-induced preconditioning. In the same way, iso-
flurane proved to be effective in rodent models of mid-
dle cerebral artery occlusion, causing increased
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[41]. In contrast to our study, these observations were all
based on pretreatment, which limits SEVO’s clinical
applicability, at least for stroke and CA patients, in whom
symptoms appear suddenly and unexpectedly. Our
results, however, suggest that SEVO administered during
reperfusion after successful CPR does not promote bene-
ficial effects, at least in terms of neurological deficits, cer-
ebral inflammation and apoptosis in this experimental
model. The absence of any neuroprotective effects of
SEVO may theoretically be rooted in the condition that
CA time was to short in our study, resulting in moderate
cerebral ischemia and low deficit scores. Indeed, Fries et
al. [44] previously reported higher NDSs and cerebral
alterations in a porcine model of 8-minute CA, but very
comparably to our data, administration of the volatile
anesthetic isoflurane after CPR did not improve neurolo-
gical deficits, neurocognitive function and ischemic
damage of neurons in the CA1 sector of the hippocam-
pus. Since ischemic damage in brain tissue may occur
much earlier than in myocardial tissue, studying only one
protocol with one type of severity of ischemic damage to
the brain cannot exclude whether, with longer or shorter
periods of global ischemia, SEVO might provide neuro-
protection. The present study results with 8 minutes of
CA, however, show that early administration of volatile
anesthetics after CPR may not improve neurological
functional outcome and therefore may be of limited
value for the preservation of neurological function.
Limitations
There are some points that need to be addressed. First,
mild therapeutic hypothermia has emerged as an effec-
tive strategy to reduce neurological impairment after
successful CPR [45]. To account for temperature depen-
dencies, however, normothermic body temperature was
maintained in both the CONTROL and SEVO groups in
the present study. Potential protective effects of volatile
anesthetics depend on energy-dependent signal trans-
duction, for example, protein synthesis and phosphoryla-
tion that may be otherwise affected by hypothermia-
induced decrease of global metabolic rate as well as sup-
pression of protein synthesis. Second, our present study
is powered for a cardiovascular end point to detect a
25% difference in left ventricular ejection fraction.
Therefore, the analysis of neurological outcome differ-
ences may be limited with this group size, although we
previously demonstrated neuroprotective effects by
induction of mild therapeutic hypothermia with a com-
parable global ischemia time [46]. Third, exposure to
SEVO longer than 4 hours might have had beneficial
effects in neurological recovery. Fourth, a few studies
have demonstrated that, to be successful, postcondition-
ing should be initiated in the very initial minutes of
reperfusion. Therefore, we cannot exclude that SEVO
had any postconditioning effect in our study, because
SEVO was started 10 minutes after stable, unassisted
circulation. Blinding the investigator was not possible
throughout the experiment because of different techni-
ques of drug administration (intravenous versus volatile
anesthetics), but echocardiographic variables and serum
and tissue samples were analyzed in a blinded fashion.
Finally, postresuscitation care was standardized up to 4
hours after ROSC, but not thereafter, and may have
affected the results 24 hours after ROSC.
Conclusions
Pharmacological postconditioning with the volatile anes-
thetic SEVO, when administered during reperfusion
after successful CPR, reduced myocardial damage and
improved myocardial dysfunction associated with
attenuation of myocardial inflammation, apoptosis,
increased HIF-1a and modulation of matrix remodeling.
On the basis of the protocol we used, we found that
early administration of SEVO may not improve neurolo-
gical recovery over propofol administration.
Key messages
￿ Postresuscitation myocardial dysfunction is a criti-
cal issue that contributes to the so-called postresus-
citation disease in patients with successful CPR.
￿ Pharmacological postconditioning with the volatile
SEVO, when administered during early reperfusion
after successful CPR, reduces myocardial damage
and myocardial dysfunction in the early period after
CPR.
￿ In addition, SEVO is associated with reduced myo-
cardial proinflammatory cytokine expression, apop-
tosis, increased HIF-1a expression and increased
activity of MMP-9.
￿ Based on the present protocol, early administration
of SEVO, however, may not improve neurological
recovery compared to propofol anesthesia
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